Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan in Infants and Children With ARPKD
NCT04782258Phase 3Recruiting
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jan 2023
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of tolvaptan in autosomal recessive polycystic kidney disease (ARPKD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Jan 2023; status: recruiting.
02
Drugs
tolvaptan
03
Conditions
autosomal recessive polycystic kidney disease (ARPKD)
Beyond the preview
Go deeper on NCT04782258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04782258.